news

Roche pays $3.5bn for 89bio and its potential best-in-disease treatment MASH drug

1
SHARES

The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.

Roche MASH

Roche is set to gain rights to a potential best-in-disease metabolic dysfunction-associated steatohepatitis (MASH) treatment by acquiring the US-based biopharma 89bio for up to $3.5 billion.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Pegozafermin’s combined anti-fibrotic and anti-inflammatory mechanism could offer a new option for moderate to severe MASH patients (liver fibrosis (F2/F3 stages) and cirrhotic MASH (F4 stage).

Thomas Schinecker, Roche Group CEO, said: “This acquisition further strengthens our portfolio in cardiovascular, renal and metabolic diseases and offers opportunities to explore combinations with existing programmes in our pipeline.

“We are highly encouraged by pegozafermin’s potential to become a transformative treatment option in MASH, one of the most prevalent comorbidities of obesity, and to meet diverse patient needs associated with this complex disease.”

We are highly encouraged by pegozafermin’s potential to become a transformative treatment option in MASH, one of the most prevalent comorbidities of obesity, and to meet diverse patient needs associated with this complex disease”

89bio’s pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) analog and currently in Phase III clinical trials for the disease.

Its GlycoPEGylation technology increases the half-life of native FGF21, enabling either weekly or every-other-week dosing.

Rohan Palekar, Chief Executive Officer of 89bio, said: “Our mission at 89bio has always been to develop innovative therapies to help patients with serious liver and cardiometabolic diseases, a commitment demonstrated by the strategic design and successful execution of the development program for pegozafermin over the years.

“We are thrilled to be joining with Roche to combine the promise of pegozafermin with Roche’s established global development, manufacturing, and commercialisation capabilities.”

MASH is formerly known as nonalcoholic fatty liver disease (NAFLD) and an estimated five to seven percent of adults are affected by it, Roche stated. “More than 75 percent of those living with the condition experience comorbidities such as overweight, obesity, and type 2 diabetes,” based on research from 2024. 

The deal is expected to close in Q4 of 2025, when all of 89bio’s current employees will join the Roche Group as part of its Pharmaceuticals Division.

Share via
Share via